|
Oct 11
|
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements
|
|
Oct 9
|
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
|
|
Oct 9
|
Clene to Present at Upcoming October Conferences
|
|
Oct 3
|
IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
|
|
Oct 2
|
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
|
|
Oct 1
|
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility
|
|
Sep 30
|
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
|
|
Sep 26
|
IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership
|
|
Aug 29
|
IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast
|
|
Aug 13
|
IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions
|
|
Aug 12
|
IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
|
|
Jun 24
|
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
|
|
Jun 21
|
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
|
Jun 11
|
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
|
|
May 28
|
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
|
|
May 14
|
Clene to Present at Upcoming May Conferences
|
|
May 9
|
Clene First Quarter 2024 Earnings: Misses Expectations
|
|
May 8
|
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
|
|
May 1
|
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
|